RSC
ABBV icon

Red Spruce Capital’s AbbVie ABBV Stock Holding History

Red Spruce Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.2M Buy
44,466
+8
+0% +$1.72K 3.9% 3
2026
Q1 		$9.67M Buy
44,458
+174
+0.4% +$38.6K 3.97% 4
2025
Q4 		$10.1M Sell
44,284
-112
-0.3% -$25.5K 4.03% 4
2025
Q3 		$10.3M Sell
44,396
-353
-0.8% -$71.9K 4.19% 3
2025
Q2 		$8.31M Sell
44,749
-1,079
-2% -$201K 3.6% 4
2025
Q1 		$9.6M Sell
45,828
-6,997
-13% -$1.36M 4.52% 4
2024
Q4 		$9.39M Buy
52,825
+77
+0.1% +$14.2K 4.17% 3
2024
Q3 		$10.4M Sell
52,748
-748
-1% -$140K 4.74% 3
2024
Q2 		$9.18M Buy
53,496
+3,816
+8% +$632K 4.26% 4
2024
Q1 		$9.05M Buy
49,680
+62
+0.1% +$10.7K 4.2% 4
2023
Q4 		$7.69M Buy
49,618
+488
+1% +$71.1K 3.95% 3
2023
Q3 		$7.32M Sell
49,130
-22
-0% -$3.23K 4.16% 4
2023
Q2 		$6.62M Buy
49,152
+10,162
+26% +$1.49M 3.57% 5
2023
Q1 		$6.21M Buy
38,990
+261
+0.7% +$39.9K 3.64% 5
2022
Q4 		$6.26M Sell
38,729
-103
-0.3% -$15.8K 3.98% 4
2022
Q3 		$5.21M Sell
38,832
-2,627
-6% -$377K 3.66% 4
2022
Q2 		$6.35M Sell
41,459
-716
-2% -$109K 4.23% 4
2022
Q1 		$6.84M Sell
42,175
-550
-1% -$79.9K 3.88% 4
2021
Q4 		$5.79M Buy
42,725
+150
+0.4% +$17.7K 3.16% 4
2021
Q3 		$4.59M Buy
42,575
+564
+1% +$64.4K 2.69% 8
2021
Q2 		$4.73M Sell
42,011
-224
-0.5% -$25.2K 2.79% 7
2021
Q1 		$4.57M Buy
42,235
+990
+2% +$106K 2.91% 6
2020
Q4 		$4.42M Buy
41,245
+930
+2% +$89.4K 3.07% 5
2020
Q3 		$3.53M Buy
40,315
+123
+0.3% +$11.6K 2.87% 7
2020
Q2 		$3.95M Sell
40,192
-429
-1% -$37.8K 3.35% 5
2020
Q1 		$3.1M Buy
40,621
+5,984
+17% +$510K 3.22% 6
2019
Q4 		$3.07M Buy
+34,637
New +$2.88M 2.56% 8

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
CRM
Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Red Spruce Capital's ABBV Position: Q2 2026 in Review

Red Spruce Capital increased its AbbVie (ABBV) stake by 0.02% in Q2 2026, buying an estimated $1.72K and bringing the position to 44,466 shares worth $11.2M. The position accounts for 3.9% of the portfolio, ranked #3.

Red Spruce Capital first reported a position in ABBV in Q4 2019 and has held it in 27 quarters since. 927 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Red Spruce Capital held 44,466 shares of AbbVie worth $11.2M as of Q2 2026.
  • Red Spruce Capital bought 8 AbbVie shares in Q2 2026, an estimated $1.72K.
  • AbbVie made up 3.9% of Red Spruce Capital's portfolio in Q2 2026, its #3 holding.
  • Red Spruce Capital first reported a position in AbbVie in Q4 2019 and has held it in 27 quarters since.
  • 927 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Red Spruce Capital's 13F filing for Q2 2026, filed 7 Jul 2026.